Clinical Trials Logo

Filter by:
NCT ID: NCT05465278 Completed - Clinical trials for Familial Hypercholesterolemia

Alirocumab and Plaque Burden In Familial Hypercholesterolaemia

ARCHITECT
Start date: May 1, 2018
Phase: Phase 4
Study type: Interventional

Low-level, open-label, multicenter clinical trial to evaluate the effect of alirocumab on the volume, architecture and composition of atherosclerotic plaque in patients with Familial hypercholesterolemia from the SAFEHEART Registry. ARCHITECT study

NCT ID: NCT05464420 Completed - Clinical trials for Pneumococcal Disease

A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Years of Age (V116-004, STRIDE-4)

Start date: August 12, 2022
Phase: Phase 3
Study type: Interventional

This study will evaluate the safety, tolerability, and immunogenicity of a pneumococcal 21-valent conjugate vaccine (V116) in pneumococcal vaccine-naïve adults 18 to 49 years of age. The primary study hypothesis is that all 3 lots of V116 are equivalent as assessed by the serotype-specific opsonophagocytic activity (OPA) Geometric Mean Titers (GMTs) at 30 days postvaccination for all serotypes included in V116.

NCT ID: NCT05463484 Completed - Oral Dysbiosis Clinical Trials

Study on the Effects of a Toothpaste in the Microbiome and Clinical Parameters in Patients With Oral Dysbiosis

Start date: July 13, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

Dysbiosis is a situation in which the normal function of an ecological net is altered. In health there is a cross talk between the host and the microbiota in order to maintain and promote a state of eubiosis. In dysbiosis a state of inflammation, a loss of hydration, a change in pH, a loss of the barrier function are all allies of key pathogens that work against the host. Stop dysbiosis is a bigger multibranch project focussed on different aspects of clinical dysbiosis including this prospective interventional double blind randomised clinical trial. Stop dysbiosis comprises further clinical studies in several areas such as oral dysbiosis, skin dysbiosis, vaginal dysbiosis and cancer dysbiosis, between others. One of the most common dysbiosis of the mouth is periodontal and mucosa dysbiosis that courses with inflammation of the gingiva (gingivitis). This inflammation induces some enzymes that in a later stage destroy connective tissue. The current study beeing presented now is focussed to research the effect of a composition with Saliactive ® topically delivered to the oral cavity vehiculized in an everyday toothpaste (YOTUEL® microbiome toothpaste) in a group of patients with oral dysbiosis.

NCT ID: NCT05462756 Completed - Type 2 Diabetes Clinical Trials

A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections

QWINT-4
Start date: August 11, 2022
Phase: Phase 3
Study type: Interventional

The reason for this study is to evaluate if the once-weekly study drug insulin efsitora alfa (LY3209590) is safe and effective compared with daily insulin glargine in participants with Type 2 diabetes (T2D) that have already been treated with basal insulin and at least 2 injections per day of prandial insulin. The study consists of a 3-week screening/lead-in period, a 26-week treatment period and a 5-week safety follow-up period. The study will last up to 34 weeks.

NCT ID: NCT05462184 Completed - Panic Disorder Clinical Trials

Predictors and Moderators of Cognitive-Behavioral Therapy and Acceptance and Commitment Therapy for Panic Disorder

Start date: March 2014
Phase: N/A
Study type: Interventional

Objective: Panic disorder is one of the most prevalent anxiety disorders and with the greatest impact on the functionality of patients. Knowing variables that influence the therapies outcome can improve the results of the interventions and reduce the socio-health cost. The current study examined possible predictors and moderators of outcome in cognitive-behavioral therapy (CBT) and acceptance and commitment therapy (ACT). Method: Eighty patients with diagnostic of panic disorder received 12 group sessions of CBT or ACT and were assessed with several measures at baseline, 12 weeks post-treatment and 24 weeks post-treatment.

NCT ID: NCT05460208 Completed - Clinical trials for Hypercholesterolemia

Hypocholesterolemic Effect of a Phytosterol-enriched Spreadable Cream Prepared With Virgin Olive Oil

Start date: January 1, 2021
Phase: N/A
Study type: Interventional

This study aims to evaluate the effect of the enriched extra virgin olive oil spread in plant sterols from the olive itself and demonstrate its effect anticholesterolemic and cardioprotective in children and adolescents with hypercholesterolemia.

NCT ID: NCT05458401 Completed - Clinical trials for HER2-positive Breast Cancer

EUropean Real-world Experience Of Previously Treated Advanced/Metastatic HER2-positive Breast Cancer Patients Accessing Trastuzumab Deruxtecan

EUROPA T-DXd
Start date: November 11, 2022
Phase:
Study type: Observational

A named patient program (NPP) was initiated to allow patients with an unmet medical need to access trastuzumab deruxtecan (T-DXd) treatment. To gain early insights on the use of T-DXd outside of a trial setting, patients with advanced/metastatic HER2+ breast cancer receiving treatment (or previously treated) with T-DXd through the NPP will be invited to participate.

NCT ID: NCT05456347 Completed - Clinical trials for Diabetes Mellitus, Type 2

Effect of a Low-calorie and High-protein Diet Specially Rich in Animal Protein Compared to a Low-calorie and High-protein Diet Specially Rich in Plant Protein on Glucose Metabolism in Subjects With Prediabetes or Type 2 Diabetes and Overweight or Obesity.

Start date: July 1, 2021
Phase: N/A
Study type: Interventional

The aim of the study is to explore the effect of a low-calorie diet rich in protein (with a content of 35% of the total calories of the diet), mostly coming from animal sources (75% of total protein), compared to a hypocaloric diet rich in protein (with a content of 35% of the total calories of the diet), mostly coming from plant sources (75% of total proteins), in subjects with prediabetes or type 2 diabetes and overweight or obesity, on body composition, glucose and lipid metabolisms, after 6 months of intervention. To achieve the objective, a nutritional intervention study is carried out by randomizing participants to: a) a hypocaloric and high-protein diet (35% of total calories), mostly of them coming from animal sources (75% of total protein); b) a hypocaloric and high-protein diet (35% of total calories), mostly of them coming from plant sources (75% of total protein). The study has a total duration of 6 months and include the assessment of clinical, anthropometric, biochemical and lifestyle parameters, at the beginning of the study and after 3 and 6 months of intervention.

NCT ID: NCT05455801 Completed - Clinical trials for Surgical Site Infection

Study to Analyze the Surgical Site Infections in a Group of Patients Who Were Randomly Applied a Negative Pressure Therapy Dressing Versus Conventional Dressing

Start date: March 1, 2019
Phase: N/A
Study type: Interventional

Surgical site complications generate a series of consequences that prolong hospital stay, increase interventions and procedures, and consequently considerably increase healthcare costs. Hence, the importance of studying measures to reduce these complications and the most feared of them is surgical site infection. The objective of the study is to analyze the complications of the surgical site in a group of participante with risk factors for developing them after undergone abdominal surgery in the period described.

NCT ID: NCT05454644 Completed - Geriatrics Clinical Trials

Effectiveness of a Person-centred Prescription Model at the End of Life

Start date: February 15, 2018
Phase: N/A
Study type: Interventional

This study's main objective is to investigate whether the application of an adapted person-centred prescription model during a hospital stay would reduce the use of inappropriate or futile regular medications in older people at the end of life, improving their clinical/health statuses and reducing the expense associated with pharmacological treatment. We hypothesised that applying this modified method could optimise pharmacotherapeutic indicators and the expense associated with the pharmacological treatment of hospitalised patients